Oncotelic Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. (OTLC) is a U.S.-based biopharmaceutical company currently quoted on the OTCQB market in the United States, and it fits the profile of a development-stage biotech whose valuation is driven by clinical, regulatory, and partnership milestones rather than mature product sales. For investors in the French-speaking market, the key takeaway is that Oncotelic positions itself around immuno-oncology, rare cancers, advanced drug-delivery technologies, and AI-enabled biomedical development. The company’s corporate headquarters are in Agoura Hills, California, United States. ([oncotelic.com](https://www.oncotelic.com/)) From a historical perspective, Oncotelic reflects a long-cycle biotech evolution and a continuation from its prior corporate identity associated with Mateon Therapeutics, as reflected in recent FDA correspondence referencing the merger/name-change history. This matters because the company’s story is less about rapid commercialization and more about assembling and repositioning a scientific asset base over time. Its development model combines in-house research, intellectual property, and joint-venture structures intended to finance and accelerate pipeline progress. ([fda.gov](https://www.fda.gov/media/182499/download)) The company’s lead program is OT-101, described by Oncotelic as its flagship immuno-oncology candidate. OT-101 is presented as a first-in-class anti-TGF-β RNA therapeutic with observed single-agent activity in relapsed/refractory cancer settings, and the company also states that it has activity against SARS-CoV-2. Beyond OT-101, Oncotelic highlights an oncology portfolio focused on rare pediatric cancers and other difficult-to-treat indications, alongside small-molecule and nanoparticle-based programs. Its website and recent updates also reference candidates and platforms such as CA4P, OXi4503, intranasal delivery concepts, and deciparticle-based development initiatives. ([oncotelic.com](https://www.oncotelic.com/)) Strategically, Oncotelic is trying to differentiate itself through a platform approach rather than a single-asset story. Management emphasizes AI-assisted biomarker discovery, translational analytics, and regulatory workflow enhancement, which suggests a broader ambition to shorten development timelines and improve target selection. That said, the company remains a small-cap biotech in a highly competitive field, where peers are numerous and differentiation depends on execution, data quality, and access to capital. It does not yet appear to be a commercial-stage pharmaceutical company; the investment case is still primarily pipeline-led. ([tmcnet.com](https://www.tmcnet.com/usubmit/-oncotelic-therapeutics-files-first-quarter-2026-financial-results-/2026/05/15/10383864.htm)) Geographically, the business is centered in the United States, with leadership and operations anchored in California, while its development and partnership footprint appears broader through clinical programs and joint ventures. Recent corporate updates indicate continued progress across OT-101 combination work, expansion of nanoparticle candidates, and further development of AI-enabled tools. In its FY2025 update, Oncotelic also highlighted a large non-cash uplift in the fair value of its JV interest and stated that operational costs tied to OT-101 and the nanoparticle platform are substantially covered by the joint venture, reducing direct funding pressure for the parent company. Management further mentioned ambitions tied to a potential Hong Kong IPO for the JV and a future uplisting to a national exchange. ([nasdaq.com](https://www.nasdaq.com/press-release/oncotelic-therapeutics-reports-fy-2025-results-highlighting-249m-net-income-and-jv))